Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively. The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Feinstein has been a leading or senior author of numerous publications in peer-reviewed journals and is named as an inventor on numerous patents.The report provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
studies (Bondi Prize for Excellence) in the Department of Chemical Immunology, the Weizmann Institute of Science, Rehovot, Israel. degree from the 2nd Moscow Medical Institute (Moscow Medical University) and completed her Ph.D.
She has a 2-year practical clinical experience from Clinical Pediatric Hospital No.1 in Moscow, Russia. Feinstein conducted research at the Weizmann Institute of Science as Doctoral Fellow, Post-Doctoral Fellow, Scientist and Senior Staff Scientist in the fields of cancer, apoptosis and functional gene discovery. Feinstein joined Quark in 1998, and since has held increasingly senior positions, including Director of Research and Development, Vice President of Research and Vice President of Technology Development. Elena Feinstein, MD, PhD., serves as CSO of Quark Pharmaceuticals Inc since 2006 and leads Quark’s technology platform development, drug discovery and non-clinical development.
0 kommentar(er)
